﻿<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.irs.gov/efile" returnVersion="2010v3.4">
  <ReturnHeader binaryAttachmentCount="0">
    <Timestamp>2011-08-05T13:59:13-05:00</Timestamp>
    <TaxPeriodEndDate>2010-12-31</TaxPeriodEndDate>
    <PreparerFirm>
      <PreparerFirmBusinessName>
        <BusinessNameLine1>O'CONNOR DAVIES MUNNS &amp; DOBBINS LLP</BusinessNameLine1>
      </PreparerFirmBusinessName>
      <PreparerFirmUSAddress>
        <AddressLine1>ONE STAMFORD LANDING</AddressLine1>
        <City>STAMFORD</City>
        <State>CT</State>
        <ZIPCode>06902</ZIPCode>
      </PreparerFirmUSAddress>
    </PreparerFirm>
    <ReturnType>990</ReturnType>
    <TaxPeriodBeginDate>2010-01-01</TaxPeriodBeginDate>
    <Filer>
      <EIN>061504413</EIN>
      <Name>
        <BusinessNameLine1>THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC</BusinessNameLine1>
      </Name>
      <NameControl>MULT</NameControl>
      <Phone>2039721250</Phone>
      <USAddress>
        <AddressLine1>383 MAIN AVE NO 5TH FL</AddressLine1>
        <City>NORWALK</City>
        <State>CT</State>
        <ZIPCode>06851</ZIPCode>
      </USAddress>
    </Filer>
    <Officer>
      <Name>KATHY GUISTI</Name>
      <Title>CEO AND FOUNDER</Title>
      <Phone>2039721250</Phone>
      <DateSigned>2011-07-28</DateSigned>
      <AuthorizeThirdParty>1</AuthorizeThirdParty>
    </Officer>
    <Preparer>
      <Name>ROBIN STRONG</Name>
      <Phone>2033232400</Phone>
    </Preparer>
    <TaxYear>2010</TaxYear>
    <BuildTS>2016-02-24 21:20:13Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCount="11">
    <IRS990 documentId="RetDoc1038000001" referenceDocumentId="RetDoc1044400001">
      <NameOfPrincipalOfficerPerson>KATHY GUISTI</NameOfPrincipalOfficerPerson>
      <AddressPrincipalOfficerUS>
        <AddressLine1>383 MAIN AVE NO 5TH FL</AddressLine1>
        <City>NORWALK</City>
        <State>CT</State>
        <ZIPCode>06851</ZIPCode>
      </AddressPrincipalOfficerUS>
      <GrossReceipts>26076479</GrossReceipts>
      <GroupReturnForAffiliates>0</GroupReturnForAffiliates>
      <Organization501c3>X</Organization501c3>
      <WebSite>WWW.THEMMRF.ORG</WebSite>
      <TypeOfOrganizationCorporation>X</TypeOfOrganizationCorporation>
      <YearFormation>1997</YearFormation>
      <StateLegalDomicile>CT</StateLegalDomicile>
      <ActivityOrMissionDescription>THE MISSION OF THE MMRF IS TO RELENTLESSLY PURSUE INNOVATIVE MEANS THAT ACCELERATE THE DEVELOPMENT OF NEXT-GENERATION MULTIPLE MYELOMA TREATMENTS TO EXTEND THE LIVES OF PATIENTS AND LEAD TO A CURE.</ActivityOrMissionDescription>
      <NbrVotingMembersGoverningBody>20</NbrVotingMembersGoverningBody>
      <NbrIndependentVotingMembers>19</NbrIndependentVotingMembers>
      <TotalNbrEmployees>26</TotalNbrEmployees>
      <TotalNbrVolunteers>10</TotalNbrVolunteers>
      <TotalGrossUBI>0</TotalGrossUBI>
      <NetUnrelatedBusinessTxblIncome>0</NetUnrelatedBusinessTxblIncome>
      <ContributionsGrantsPriorYear>21845537</ContributionsGrantsPriorYear>
      <ContributionsGrantsCurrentYear>25650253</ContributionsGrantsCurrentYear>
      <ProgramServiceRevenuePriorYear>0</ProgramServiceRevenuePriorYear>
      <ProgramServiceRevenueCY>0</ProgramServiceRevenueCY>
      <InvestmentIncomePriorYear>68343</InvestmentIncomePriorYear>
      <InvestmentIncomeCurrentYear>146601</InvestmentIncomeCurrentYear>
      <OtherRevenuePriorYear>-1183880</OtherRevenuePriorYear>
      <OtherRevenueCurrentYear>-1589455</OtherRevenueCurrentYear>
      <TotalRevenuePriorYear>20730000</TotalRevenuePriorYear>
      <TotalRevenueCurrentYear>24207399</TotalRevenueCurrentYear>
      <GrantsAndSimilarAmntsPriorYear>12587247</GrantsAndSimilarAmntsPriorYear>
      <GrantsAndSimilarAmntsCY>13614779</GrantsAndSimilarAmntsCY>
      <BenefitsPaidToMembersPriorYear>0</BenefitsPaidToMembersPriorYear>
      <BenefitsPaidToMembersCY>0</BenefitsPaidToMembersCY>
      <SalariesEtcPriorYear>1904518</SalariesEtcPriorYear>
      <SalariesEtcCurrentYear>2155037</SalariesEtcCurrentYear>
      <TotalProfFundrsngExpPriorYear>70000</TotalProfFundrsngExpPriorYear>
      <TotalProfFundrsngExpCY>151374</TotalProfFundrsngExpCY>
      <TotalFundrsngExpCurrentYear>1536356</TotalFundrsngExpCurrentYear>
      <OtherExpensePriorYear>3502094</OtherExpensePriorYear>
      <OtherExpensesCurrentYear>4219834</OtherExpensesCurrentYear>
      <TotalExpensesPriorYear>18063859</TotalExpensesPriorYear>
      <TotalExpensesCurrentYear>20141024</TotalExpensesCurrentYear>
      <RevenuesLessExpensesPriorYear>2666141</RevenuesLessExpensesPriorYear>
      <RevenuesLessExpensesCY>4066375</RevenuesLessExpensesCY>
      <TotalAssetsBOY>20585093</TotalAssetsBOY>
      <TotalAssetsEOY>25514760</TotalAssetsEOY>
      <TotalLiabilitiesBOY>11498195</TotalLiabilitiesBOY>
      <TotalLiabilitiesEOY>12303143</TotalLiabilitiesEOY>
      <NetAssetsOrFundBalancesBOY>9086898</NetAssetsOrFundBalancesBOY>
      <NetAssetsOrFundBalancesEOY>13211617</NetAssetsOrFundBalancesEOY>
      <InfoInScheduleOPartIII>X</InfoInScheduleOPartIII>
      <MissionDescription>THE MISSION OF THE MMRF IS TO RELENTLESSLY PURSUE INNOVATIVE MEANS THAT ACCELERATE THE DEVELOPMENT OF NEXT-GENERATION MULTIPLE MYELOMA TREATMENTS TO EXTEND THE LIVES OF PATIENTS AND LEAD TO A CURE.</MissionDescription>
      <SignificantNewProgramServices>1</SignificantNewProgramServices>
      <SignificantChange>0</SignificantChange>
      <Expense>4145000</Expense>
      <Grants>4145000</Grants>
      <Description>MULTIPLE MYELOMA RESEARCH CONSORTIUM AWARD (1 ORGANIZATION):THE MMRC INTEGRATES RESEARCH EFFORTS FROM MYELOMA RESEARCH CENTERS AND CREATES A SHARED RESEARCH ENVIRONMENT.</Description>
      <Activity2>
        <Expense>2800000</Expense>
        <Grants>2800000</Grants>
        <Description>SENIOR RESEARCH GRANT AWARD PROGRAM (14 GRANTED IN 2010):THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) SUPPORTS INVESTIGATORS WITH MORE THAN FIVE YEARS OF EXPERIENCE IN BLOOD CANCER RESEARCH. THE GOAL OF THIS INITIATIVE IS TO ACCELERATE THE DEVELOPMENT OF THERAPEUTIC APPROACHES FOR MYELOMA AND MAY INCLUDE PROPOSALS IN BASIC SCIENCE, VALIDATION, OR TRANSLATION RESEARCH.</Description>
      </Activity2>
      <Activity3>
        <Expense>2500000</Expense>
        <Grants>2500000</Grants>
        <Description>BIOTECH INVESTMENT AWARD (5 AWARDEES IN 2010): THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) SEEKS PROPOSALS FOR ITS BIOTECH INVESTMENT AWARD PROGRAM (BIA). THE GOAL OF THIS INITIATIVE IS TO DRIVE AND ACCELERATE THE DEVELOPMENT OF INNOVATIVE AND EFFECTIVE TREATMENTS FOR MYELOMA. THIS PROGRAM IS DESIGNED TO: A) PROVIDE RESOURCES NECESSARY FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES TO RAPIDLY TEST THERAPEUTICS IN MULTIPLE MYELOMA; AND B) TO FOSTER COLLABORATION WITH ACADEMIC MYELOMA EXPERTS, AS NEEDED. BIA AIMS TO REMOVE BARRIERS THAT LIMIT THE DEVELOPMENT OF NOVEL DRUGS FOR MYELOMA.</Description>
      </Activity3>
      <ActivityOther>
        <Expense>8633987</Expense>
        <Grants>4169779</Grants>
        <Description>IN ADDITION TO THE PROGRAM EXPENSES DESCRIBED ABOVE, CORRESPONDING ACTIVITIES IN ALIGNMENT WITH THE OVERALL GOALS OF THE ORGANIZATION ARE ALSO SUPPORTED. THESE INCLUDE A PORTFOLIO OF CUTTING-EDGE RESEARCH PROGRAMS IN BASIC SCIENCE, WHICH INDENTIFIES NEW TARGETS THROUGH GENOMICS AND PROTEOMICS RESEARCH; VALIDATION STUDIES, WHICH IDENTIFY NEW COMPOUNDS AND COMBINATIONS IN RESEARCH MODELS BASED ON HIGH-PRIORITY TARGETS; AND INNOVATIVE CLINICAL TRIALS OF NOVEL AND COMBINATION TREATMENTS. ALSO, THE MMRF DEVELOPS AND IMPLEMENTS EXTENSIVE EDUCATIONAL PROGRAMMING FOR HEALTHCARE PROFESSIONALS AND FOR PATIENTS AND CAREGIVERS.</Description>
      </ActivityOther>
      <TotalOfOtherProgramServiceExp>8633987</TotalOfOtherProgramServiceExp>
      <TotalOfOtherProgramServiceGrnt>4169779</TotalOfOtherProgramServiceGrnt>
      <TotalProgramServiceExpense>18078987</TotalProgramServiceExpense>
      <DescribedIn501C3 referenceDocumentId="RetDoc1039100001">1</DescribedIn501C3>
      <ScheduleBRequired referenceDocumentId="RetDoc1234500001">1</ScheduleBRequired>
      <PoliticalActivities>0</PoliticalActivities>
      <LobbyingActivities>0</LobbyingActivities>
      <DonorAdvisedFunds referenceDocumentId="RetDoc1040000001">0</DonorAdvisedFunds>
      <ConservationEasements referenceDocumentId="RetDoc1040000001">0</ConservationEasements>
      <CollectionsOfArt referenceDocumentId="RetDoc1040000001">0</CollectionsOfArt>
      <CreditCounseling referenceDocumentId="RetDoc1040000001">0</CreditCounseling>
      <TermOrPermanentEndowments referenceDocumentId="RetDoc1040000001">0</TermOrPermanentEndowments>
      <ReportLandBldgEquip referenceDocumentId="RetDoc1040000001">1</ReportLandBldgEquip>
      <ReportInvestOthSecurities referenceDocumentId="RetDoc1040000001">0</ReportInvestOthSecurities>
      <ReportProgRelInvest referenceDocumentId="RetDoc1040000001">0</ReportProgRelInvest>
      <ReportOtherAssets referenceDocumentId="RetDoc1040000001">0</ReportOtherAssets>
      <ReportOtherLiabilities referenceDocumentId="RetDoc1040000001">1</ReportOtherLiabilities>
      <ReportFin48Footnote referenceDocumentId="RetDoc1040000001">1</ReportFin48Footnote>
      <IndependentAuditFinancialStmt referenceDocumentId="RetDoc1040000001">1</IndependentAuditFinancialStmt>
      <ConsolidatedAuditFinancialStmt referenceDocumentId="RetDoc1040000001">1</ConsolidatedAuditFinancialStmt>
      <School>0</School>
      <ForeignOffice>0</ForeignOffice>
      <ForeignActivities referenceDocumentId="RetDoc1040500001">1</ForeignActivities>
      <MoreThan5000KToOrganizations referenceDocumentId="RetDoc1040500001">1</MoreThan5000KToOrganizations>
      <MoreThan5000KToIndividuals referenceDocumentId="RetDoc1040500001">0</MoreThan5000KToIndividuals>
      <ProfessionalFundraising referenceDocumentId="RetDoc1041200001">1</ProfessionalFundraising>
      <FundraisingActivities referenceDocumentId="RetDoc1041200001">1</FundraisingActivities>
      <Gaming referenceDocumentId="RetDoc1041200001">0</Gaming>
      <Hospital>0</Hospital>
      <GrantsToOrganizations referenceDocumentId="RetDoc1041900001">1</GrantsToOrganizations>
      <GrantsToIndividuals referenceDocumentId="RetDoc1041900001">0</GrantsToIndividuals>
      <ScheduleJRequired referenceDocumentId="RetDoc1042400001">1</ScheduleJRequired>
      <TaxExemptBonds>0</TaxExemptBonds>
      <ExcessBenefitTransaction>0</ExcessBenefitTransaction>
      <PriorExcessBenefitTransaction>0</PriorExcessBenefitTransaction>
      <LoanToOfficerOrDQP>0</LoanToOfficerOrDQP>
      <GrantToRelatedPerson>0</GrantToRelatedPerson>
      <BsnssRltnshpWithOrganization>0</BsnssRltnshpWithOrganization>
      <BsnssRltnshpThruFamilyMember>0</BsnssRltnshpThruFamilyMember>
      <OfficerEntityWithBsnssRltnshp>0</OfficerEntityWithBsnssRltnshp>
      <DeductibleNonCashContributions referenceDocumentId="RetDoc1042900001">1</DeductibleNonCashContributions>
      <DeductibleContributionsOfArt referenceDocumentId="RetDoc1042900001">0</DeductibleContributionsOfArt>
      <Terminated>0</Terminated>
      <PartialLiquidation>0</PartialLiquidation>
      <DisregardedEntity referenceDocumentId="RetDoc1043400001">0</DisregardedEntity>
      <RelatedEntity referenceDocumentId="RetDoc1043400001">1</RelatedEntity>
      <RelatedOrgControlledEntity>0</RelatedOrgControlledEntity>
      <TransactionRelatedEntity referenceDocumentId="RetDoc1043400001">0</TransactionRelatedEntity>
      <TransfersToExemptNonChrtblOrg referenceDocumentId="RetDoc1043400001">0</TransfersToExemptNonChrtblOrg>
      <ActivitiesConductedPartnership referenceDocumentId="RetDoc1043400001">0</ActivitiesConductedPartnership>
      <ScheduleORequired>1</ScheduleORequired>
      <NumberFormsTransmittedWith1096>42</NumberFormsTransmittedWith1096>
      <NumberW2GIncluded>0</NumberW2GIncluded>
      <ComplianceWithBackupWitholding>1</ComplianceWithBackupWitholding>
      <NumberOfEmployees>26</NumberOfEmployees>
      <EmploymentTaxReturnsFiled>1</EmploymentTaxReturnsFiled>
      <UnrelatedBusinessIncome>0</UnrelatedBusinessIncome>
      <ForeignFinancialAccount>0</ForeignFinancialAccount>
      <ProhibitedTaxShelterTrans>0</ProhibitedTaxShelterTrans>
      <TaxablePartyNotification>0</TaxablePartyNotification>
      <NonDeductibleContributions>0</NonDeductibleContributions>
      <QuidProQuoContributions>1</QuidProQuoContributions>
      <QuidProQuoDisclosure>1</QuidProQuoDisclosure>
      <Form8282PropertyDisposedOf>0</Form8282PropertyDisposedOf>
      <IndoorTanningServices>0</IndoorTanningServices>
      <InfoInScheduleOPartVI>X</InfoInScheduleOPartVI>
      <NbrVotingGoverningBodyMembers>20</NbrVotingGoverningBodyMembers>
      <NumberIndependentVotingMembers>19</NumberIndependentVotingMembers>
      <FamilyOrBusinessRelationship>1</FamilyOrBusinessRelationship>
      <DelegationOfManagementDuties>1</DelegationOfManagementDuties>
      <ChangesToOrganizingDocs>0</ChangesToOrganizingDocs>
      <MaterialDiversionOrMisuse>0</MaterialDiversionOrMisuse>
      <MembersOrStockholders>0</MembersOrStockholders>
      <ElectionOfBoardMembers>0</ElectionOfBoardMembers>
      <DecisionsSubjectToApproval>0</DecisionsSubjectToApproval>
      <MinutesOfGoverningBody>1</MinutesOfGoverningBody>
      <MinutesOfCommittees>1</MinutesOfCommittees>
      <OfficerMailingAddress>0</OfficerMailingAddress>
      <LocalChapters>0</LocalChapters>
      <Form990ProvidedToGoverningBody>0</Form990ProvidedToGoverningBody>
      <ConflictOfInterestPolicy>1</ConflictOfInterestPolicy>
      <AnnualDisclosureCoveredPersons>1</AnnualDisclosureCoveredPersons>
      <RegularMonitoringEnforcement>1</RegularMonitoringEnforcement>
      <WhistleblowerPolicy>1</WhistleblowerPolicy>
      <DocumentRetentionPolicy>1</DocumentRetentionPolicy>
      <CompensationProcessCEO>1</CompensationProcessCEO>
      <CompensationProcessOther>1</CompensationProcessOther>
      <InvestmentInJointVenture>0</InvestmentInJointVenture>
      <StatesWhereCopyOfReturnIsFiled>CT</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>AK</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>AR</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>CA</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>FL</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>GA</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>HI</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>KY</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>ME</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>MD</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>MA</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>MI</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>MS</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>NH</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>NJ</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>NM</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>NY</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>OK</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>PA</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>WV</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>AL</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>AZ</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>CO</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>IL</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>MN</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>NC</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>OH</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>RI</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>SC</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>TN</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>UT</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>VA</StatesWhereCopyOfReturnIsFiled>
      <StatesWhereCopyOfReturnIsFiled>WI</StatesWhereCopyOfReturnIsFiled>
      <OwnWebsite>X</OwnWebsite>
      <UponRequest>X</UponRequest>
      <TheBooksAreInCareOf>
        <NameBusiness>
          <BusinessNameLine1>JIM GRAZICK</BusinessNameLine1>
        </NameBusiness>
        <TelephoneNumber>2036520231</TelephoneNumber>
        <AddressUS>
          <AddressLine1>383 MAIN AVE 5TH FLOOR</AddressLine1>
          <City>NORWALK</City>
          <State>CT</State>
          <ZIPCode>06851</ZIPCode>
        </AddressUS>
      </TheBooksAreInCareOf>
      <Form990PartVIISectionA>
        <NamePerson>ALAN HELLER</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>CHARLES ORTNER</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>CHRIS MCWILTON</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>DANA LAFORGE</NamePerson>
        <Title>CHAIRMAN</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <Officer>X</Officer>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>DONNA ZACCARO</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>EDWARD PHILLIPS</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>FRANK DOUGLAS PHD</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>GENE GRISANTI</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>GERALD MCDOUGALL</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>KAREN ANDREWS</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>KATHY GIUSTI</NamePerson>
        <Title>CHIEF EXECUTIVE OFFICER, PRESIDENT</Title>
        <AverageHoursPerWeek>30.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <Officer>X</Officer>
        <ReportableCompFromOrganization>311413</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>KENNETH ANDERSON MD</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>LORI TAUBER-MARCUS</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>MERYL ZAUSNER</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>MIKE MORTIMER</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>ROBERT BEALL PHD</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>STEPHEN GRAND</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>WILLIAM MCKIERNAN</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>DAVID PARKINSON</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>ANTHONY KESMAN</NamePerson>
        <Title>BOARD MEMBER</Title>
        <AverageHoursPerWeek>2.00</AverageHoursPerWeek>
        <IndividualTrusteeOrDirector>X</IndividualTrusteeOrDirector>
        <ReportableCompFromOrganization>0</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>ANNE QUINN YOUNG</NamePerson>
        <Title>VP OF COMMUNICATIONS</Title>
        <AverageHoursPerWeek>36.00</AverageHoursPerWeek>
        <Officer>X</Officer>
        <ReportableCompFromOrganization>139086</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>KAREN DIETZ</NamePerson>
        <Title>SECRETARY/IN-HOUSE COUNCIL</Title>
        <AverageHoursPerWeek>32.00</AverageHoursPerWeek>
        <Officer>X</Officer>
        <ReportableCompFromOrganization>78883</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>STEVE AMELIO</NamePerson>
        <Title>CHIEF FINANCIAL OFFICER</Title>
        <AverageHoursPerWeek>6.40</AverageHoursPerWeek>
        <Officer>X</Officer>
        <ReportableCompFromOrganization>7692</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>WALTER CAPONE</NamePerson>
        <Title>CHIEF OPERATING OFFICER</Title>
        <AverageHoursPerWeek>30.00</AverageHoursPerWeek>
        <Officer>X</Officer>
        <ReportableCompFromOrganization>152613</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>JAMES GRAZICK</NamePerson>
        <Title>TREASURER/DIRECTOR OF FINANCE</Title>
        <AverageHoursPerWeek>32.00</AverageHoursPerWeek>
        <Officer>X</Officer>
        <ReportableCompFromOrganization>80329</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>LOUISE PERKINS</NamePerson>
        <Title>CHIEF SCIENTIFIC OFFICER</Title>
        <AverageHoursPerWeek>28.00</AverageHoursPerWeek>
        <KeyEmployee>X</KeyEmployee>
        <ReportableCompFromOrganization>208031</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>ANNE WALKER</NamePerson>
        <Title>NATIONAL EVENTS DIRECTOR</Title>
        <AverageHoursPerWeek>40.00</AverageHoursPerWeek>
        <HighestCompensatedEmployee>X</HighestCompensatedEmployee>
        <ReportableCompFromOrganization>138713</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>JOAN LEVY</NamePerson>
        <Title>ASS. DR. OF RESEARCH</Title>
        <AverageHoursPerWeek>40.00</AverageHoursPerWeek>
        <HighestCompensatedEmployee>X</HighestCompensatedEmployee>
        <ReportableCompFromOrganization>136817</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <Form990PartVIISectionA>
        <NamePerson>ROBERT LUCAS</NamePerson>
        <Title>VP OF DEVELOPMENT</Title>
        <AverageHoursPerWeek>40.00</AverageHoursPerWeek>
        <HighestCompensatedEmployee>X</HighestCompensatedEmployee>
        <ReportableCompFromOrganization>200417</ReportableCompFromOrganization>
        <ReportableCompFromRelatedOrgs>0</ReportableCompFromRelatedOrgs>
        <OtherCompensation>0</OtherCompensation>
      </Form990PartVIISectionA>
      <TotalReportableCompFromOrg>1453994</TotalReportableCompFromOrg>
      <TotalReportableCompFrmRltdOrgs>0</TotalReportableCompFrmRltdOrgs>
      <TotalOtherCompensation>0</TotalOtherCompensation>
      <NumberIndividualsGT100K>7</NumberIndividualsGT100K>
      <FormersListed>0</FormersListed>
      <TotalCompGT150K>1</TotalCompGT150K>
      <CompensationFromOtherSources>0</CompensationFromOtherSources>
      <ContractorCompensation>
        <NameOfContractor>
          <NameBusiness>
            <BusinessNameLine1>AOI COMMUNCIATIONS</BusinessNameLine1>
          </NameBusiness>
        </NameOfContractor>
        <AddressOfContractor>
          <AddressUS>
            <AddressLine1>102 PICKERING WAY</AddressLine1>
            <City>EXTON</City>
            <State>PA</State>
            <ZIPCode>19341</ZIPCode>
          </AddressUS>
        </AddressOfContractor>
        <DescriptionOfServices>MEETING AND EVENT PLANNER</DescriptionOfServices>
        <Compensation>386499</Compensation>
      </ContractorCompensation>
      <ContractorCompensation>
        <NameOfContractor>
          <NameBusiness>
            <BusinessNameLine1>PRICEWATERHOUSECOOPERS</BusinessNameLine1>
          </NameBusiness>
        </NameOfContractor>
        <AddressOfContractor>
          <AddressUS>
            <AddressLine1>2001 MARKET STREET SUITE 1700</AddressLine1>
            <City>PHILADELPHIA</City>
            <State>PA</State>
            <ZIPCode>19103</ZIPCode>
          </AddressUS>
        </AddressOfContractor>
        <DescriptionOfServices>MANAGEMENT CONSULTING</DescriptionOfServices>
        <Compensation>281728</Compensation>
      </ContractorCompensation>
      <NumberOfContractorsGT100K>2</NumberOfContractorsGT100K>
      <FundraisingEvents>6853409</FundraisingEvents>
      <GovernmentGrants>392759</GovernmentGrants>
      <AllOtherContributions>18404085</AllOtherContributions>
      <TotalContributions>25650253</TotalContributions>
      <InvestmentIncome>
        <TotalRevenueColumn>146601</TotalRevenueColumn>
        <ExclusionAmount>146601</ExclusionAmount>
      </InvestmentIncome>
      <GrossIncomeFundraisingEvents>279625</GrossIncomeFundraisingEvents>
      <CntrbtnsRprtdFundraisingEvents>6853409</CntrbtnsRprtdFundraisingEvents>
      <FundraisingDirectExpenses>1869080</FundraisingDirectExpenses>
      <NetIncomeFromFundraisingEvents>
        <TotalRevenueColumn>-1589455</TotalRevenueColumn>
        <ExclusionAmount>-1589455</ExclusionAmount>
      </NetIncomeFromFundraisingEvents>
      <TotalRevenue>
        <TotalRevenueColumn>24207399</TotalRevenueColumn>
        <RelatedOrExemptFunctionIncome>0</RelatedOrExemptFunctionIncome>
        <UnrelatedBusinessRevenue>0</UnrelatedBusinessRevenue>
        <ExclusionAmount>-1442854</ExclusionAmount>
      </TotalRevenue>
      <GrantsToDomesticOrgs>
        <Total>11764779</Total>
        <ProgramServices>11764779</ProgramServices>
      </GrantsToDomesticOrgs>
      <ForeignGrants>
        <Total>1850000</Total>
        <ProgramServices>1850000</ProgramServices>
      </ForeignGrants>
      <CompCurrentOfficersDirectors>
        <Total>914642</Total>
        <ProgramServices>607358</ProgramServices>
        <ManagementAndGeneral>190572</ManagementAndGeneral>
        <Fundraising>116712</Fundraising>
      </CompCurrentOfficersDirectors>
      <OtherSalariesAndWages>
        <Total>1240395</Total>
        <ProgramServices>496021</ProgramServices>
        <ManagementAndGeneral>165009</ManagementAndGeneral>
        <Fundraising>579365</Fundraising>
      </OtherSalariesAndWages>
      <FeesForServicesProfFundraising>
        <Total>151374</Total>
        <Fundraising>151374</Fundraising>
      </FeesForServicesProfFundraising>
      <FeesForServicesOther>
        <Total>907553</Total>
        <ProgramServices>416674</ProgramServices>
        <ManagementAndGeneral>69902</ManagementAndGeneral>
        <Fundraising>420977</Fundraising>
      </FeesForServicesOther>
      <Advertising>
        <Total>135092</Total>
        <ProgramServices>121583</ProgramServices>
        <Fundraising>13509</Fundraising>
      </Advertising>
      <OfficeExpenses>
        <Total>114491</Total>
        <ProgramServices>60885</ProgramServices>
        <ManagementAndGeneral>18125</ManagementAndGeneral>
        <Fundraising>35481</Fundraising>
      </OfficeExpenses>
      <Occupancy>
        <Total>206283</Total>
        <ProgramServices>105617</ProgramServices>
        <ManagementAndGeneral>34037</ManagementAndGeneral>
        <Fundraising>66629</Fundraising>
      </Occupancy>
      <Travel>
        <Total>95877</Total>
        <ProgramServices>13916</ProgramServices>
        <ManagementAndGeneral>5964</ManagementAndGeneral>
        <Fundraising>75997</Fundraising>
      </Travel>
      <ConferencesMeetings>
        <Total>1322777</Total>
        <ProgramServices>1321953</ProgramServices>
        <ManagementAndGeneral>412</ManagementAndGeneral>
        <Fundraising>412</Fundraising>
      </ConferencesMeetings>
      <DepreciationDepletion>
        <Total>107349</Total>
        <ProgramServices>54963</ProgramServices>
        <ManagementAndGeneral>17713</ManagementAndGeneral>
        <Fundraising>34673</Fundraising>
      </DepreciationDepletion>
      <Insurance>
        <Total>59019</Total>
        <ProgramServices>47215</ProgramServices>
        <ManagementAndGeneral>5902</ManagementAndGeneral>
        <Fundraising>5902</Fundraising>
      </Insurance>
      <OtherExpenses>
        <Description>PATIENT AND CLINICIAN O</Description>
        <Total>767731</Total>
        <ProgramServices>767731</ProgramServices>
        <ManagementAndGeneral>0</ManagementAndGeneral>
        <Fundraising>0</Fundraising>
      </OtherExpenses>
      <OtherExpenses>
        <Description>CDC EXPENSE</Description>
        <Total>394296</Total>
        <ProgramServices>394296</ProgramServices>
        <ManagementAndGeneral>0</ManagementAndGeneral>
        <Fundraising>0</Fundraising>
      </OtherExpenses>
      <OtherExpenses>
        <Description>MISCELLANEOUS</Description>
        <Total>109366</Total>
        <ProgramServices>55996</ProgramServices>
        <ManagementAndGeneral>18045</ManagementAndGeneral>
        <Fundraising>35325</Fundraising>
      </OtherExpenses>
      <TotalFunctionalExpenses>
        <Total>20141024</Total>
        <ProgramServices>18078987</ProgramServices>
        <ManagementAndGeneral>525681</ManagementAndGeneral>
        <Fundraising>1536356</Fundraising>
      </TotalFunctionalExpenses>
      <CashNonInterestBearing>
        <BOY>500</BOY>
        <EOY>500</EOY>
      </CashNonInterestBearing>
      <SavingsAndTempCashInvestments>
        <BOY>8625596</BOY>
        <EOY>12319250</EOY>
      </SavingsAndTempCashInvestments>
      <PledgesAndGrantsReceivable>
        <BOY>7677383</BOY>
        <EOY>7928343</EOY>
      </PledgesAndGrantsReceivable>
      <PrepaidExpensesDeferredCharges>
        <BOY>114604</BOY>
        <EOY>263243</EOY>
      </PrepaidExpensesDeferredCharges>
      <LandBuildingsEquipmentBasis>649095</LandBuildingsEquipmentBasis>
      <LandBldgEquipmentAccumDeprec>404772</LandBldgEquipmentAccumDeprec>
      <LandBuildingsEquipmentBasisNet>
        <BOY>345877</BOY>
        <EOY>244323</EOY>
      </LandBuildingsEquipmentBasisNet>
      <InvestmentsPubTradedSecurities>
        <BOY>3568171</BOY>
        <EOY>4567673</EOY>
      </InvestmentsPubTradedSecurities>
      <OtherAssetsTotal>
        <BOY>252962</BOY>
        <EOY>191428</EOY>
      </OtherAssetsTotal>
      <TotalAssets>
        <BOY>20585093</BOY>
        <EOY>25514760</EOY>
      </TotalAssets>
      <AccountsPayableAccruedExpenses>
        <BOY>337426</BOY>
        <EOY>430737</EOY>
      </AccountsPayableAccruedExpenses>
      <GrantsPayable>
        <BOY>10173071</BOY>
        <EOY>11240911</EOY>
      </GrantsPayable>
      <DeferredRevenue>
        <BOY>7698</BOY>
        <EOY>131495</EOY>
      </DeferredRevenue>
      <OtherLiabilities>
        <BOY>980000</BOY>
        <EOY>500000</EOY>
      </OtherLiabilities>
      <TotalLiabilities>
        <BOY>11498195</BOY>
        <EOY>12303143</EOY>
      </TotalLiabilities>
      <FollowSFAS117>X</FollowSFAS117>
      <UnrestrictedNetAssets>
        <BOY>7633073</BOY>
        <EOY>2866617</EOY>
      </UnrestrictedNetAssets>
      <TemporarilyRestrictedNetAssets>
        <BOY>1453825</BOY>
        <EOY>10345000</EOY>
      </TemporarilyRestrictedNetAssets>
      <TotalNetAssetsFundBalances>
        <BOY>9086898</BOY>
        <EOY>13211617</EOY>
      </TotalNetAssetsFundBalances>
      <TotalLiabNetAssetsFundBalances>
        <BOY>20585093</BOY>
        <EOY>25514760</EOY>
      </TotalLiabNetAssetsFundBalances>
      <InfoInScheduleOPartXI>X</InfoInScheduleOPartXI>
      <ReconcilationRevenueExpenses>4066375</ReconcilationRevenueExpenses>
      <ReconcilationOtherChanges>58344</ReconcilationOtherChanges>
      <InfoInScheduleOPartXII>X</InfoInScheduleOPartXII>
      <MethodOfAccountingAccrual>X</MethodOfAccountingAccrual>
      <AccountantCompileOrReview>0</AccountantCompileOrReview>
      <FSAudited>1</FSAudited>
      <AuditCommittee>1</AuditCommittee>
      <FinancialStatementBoth>X</FinancialStatementBoth>
      <FederalGrantAuditRequired>0</FederalGrantAuditRequired>
    </IRS990>
    <IRS990ScheduleA documentId="RetDoc1039100001">
      <PubliclySupportedOrg170b1Avi>X</PubliclySupportedOrg170b1Avi>
      <GiftsGrantsContribReceived170>
        <CurrentTaxYearMinus4Years>14704606</CurrentTaxYearMinus4Years>
        <CurrentTaxYearMinus3Years>22305441</CurrentTaxYearMinus3Years>
        <CurrentTaxYearMinus2Years>22400673</CurrentTaxYearMinus2Years>
        <CurrentTaxYearMinus1Year>21845537</CurrentTaxYearMinus1Year>
        <CurrentTaxYear>25650253</CurrentTaxYear>
        <Total>106906510</Total>
      </GiftsGrantsContribReceived170>
      <Total170>
        <CurrentTaxYearMinus4Years>14704606</CurrentTaxYearMinus4Years>
        <CurrentTaxYearMinus3Years>22305441</CurrentTaxYearMinus3Years>
        <CurrentTaxYearMinus2Years>22400673</CurrentTaxYearMinus2Years>
        <CurrentTaxYearMinus1Year>21845537</CurrentTaxYearMinus1Year>
        <CurrentTaxYear>25650253</CurrentTaxYear>
        <Total>106906510</Total>
      </Total170>
      <AmountsSubstContributorsTotal>22672197</AmountsSubstContributorsTotal>
      <PublicSupportTotal170>84234313</PublicSupportTotal170>
      <GrossInvestmentIncome170>
        <CurrentTaxYearMinus4Years>265162</CurrentTaxYearMinus4Years>
        <CurrentTaxYearMinus3Years>245441</CurrentTaxYearMinus3Years>
        <CurrentTaxYearMinus2Years>113486</CurrentTaxYearMinus2Years>
        <CurrentTaxYearMinus1Year>68343</CurrentTaxYearMinus1Year>
        <CurrentTaxYear>146601</CurrentTaxYear>
        <Total>839033</Total>
      </GrossInvestmentIncome170>
      <TotalSupport>107745543</TotalSupport>
      <GrossReceiptsFromAdmissionsEtc>949858</GrossReceiptsFromAdmissionsEtc>
      <PublicSupportPertcentage170>0.78180</PublicSupportPertcentage170>
      <PublicSupportPertcentPriorYear>0.78970</PublicSupportPertcentPriorYear>
      <ThirtyThreePercntTestsCY170>X</ThirtyThreePercntTestsCY170>
    </IRS990ScheduleA>
    <IRS990ScheduleB documentId="RetDoc1234500001">
      <ContributorInfo>
        <ContributorNumber>RESTRICTED</ContributorNumber>
        <ContributorNameBusiness>
          <BusinessNameLine1>RESTRICTED</BusinessNameLine1>
        </ContributorNameBusiness>
        <ContributorAddressUS>
          <AddressLine1>RESTRICTED</AddressLine1>
          <AddressLine2>RESTRICTED</AddressLine2>
          <City>RESTRICTED</City>
          <State>RESTRICTED</State>
          <ZIPCode>RESTRICTED</ZIPCode>
        </ContributorAddressUS>
        <AggregateContributions>RESTRICTED</AggregateContributions>
      </ContributorInfo>
    </IRS990ScheduleB>
    <IRS990ScheduleD documentId="RetDoc1040000001">
      <Equipment>
        <OtherCostOrOtherBasis>282943</OtherCostOrOtherBasis>
        <Depreciation>209401</Depreciation>
        <BookValue>73542</BookValue>
      </Equipment>
      <OtherLandBuildings>
        <OtherCostOrOtherBasis>366152</OtherCostOrOtherBasis>
        <Depreciation>195371</Depreciation>
        <BookValue>170781</BookValue>
      </OtherLandBuildings>
      <TotalOfBookValueLandBuildings>244323</TotalOfBookValueLandBuildings>
      <OtherLiabilities>
        <Description>MMRC RESEARCH GRANT PAYABLE</Description>
        <Amount>500000</Amount>
      </OtherLiabilities>
      <TotalOfAmounts>500000</TotalOfAmounts>
      <TotalRevenue>24207399</TotalRevenue>
      <TotalExpenses>20141024</TotalExpenses>
      <ExcessOrDeficitForYear>4066375</ExcessOrDeficitForYear>
      <NetUnrealizedGLOnInvestments>58346</NetUnrealizedGLOnInvestments>
      <OtherAmount>-2</OtherAmount>
      <TotalAdjustments>58344</TotalAdjustments>
      <ExcessOrDeficitPerFS>4124719</ExcessOrDeficitPerFS>
      <TotRevenueEtcAuditedFinclStmt>24329799</TotRevenueEtcAuditedFinclStmt>
      <NetUnrealizedGainsInvestments>58346</NetUnrealizedGainsInvestments>
      <DonatedSrvcAndUseOfFacilities>64054</DonatedSrvcAndUseOfFacilities>
      <RevenueNotRptdF990>122400</RevenueNotRptdF990>
      <RevenueSubtotal>24207399</RevenueSubtotal>
      <RevenueNotRptdOnFinStmt>0</RevenueNotRptdOnFinStmt>
      <TotalRevenuePerForm990>24207399</TotalRevenuePerForm990>
      <TotExpensesEtcAuditedFinclStmt>20205080</TotExpensesEtcAuditedFinclStmt>
      <DonatedServicesUseOfFacilities>64054</DonatedServicesUseOfFacilities>
      <LossesReported>2</LossesReported>
      <ExpensesNotRptdF990>64056</ExpensesNotRptdF990>
      <ExpensesSubtotal>20141024</ExpensesSubtotal>
      <ExpensesNotRptdOnFinStmt>0</ExpensesNotRptdOnFinStmt>
      <TotalExpensesPerForm990>20141024</TotalExpensesPerForm990>
      <Form990ScheduleDPartXIV>
        <Identifier>DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48:</Identifier>
        <ReturnReference>PART X:</ReturnReference>
        <Explanation>THE FOUNDATION RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED. MANAGEMENT HAS DETERMINED THAT THE FOUNDATION HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION. THE FOUNDATION IS NO LONGER SUBJECT TO AUDITS BY THE APPLICABLE TAXING JURISDICTIONS FOR PERIOD PRIOR TO 2007.</Explanation>
      </Form990ScheduleDPartXIV>
      <Form990ScheduleDPartXIV>
        <Explanation>SCHEDULE D, PAGE 4, PART XII, QUESTION 4B. AMOUNTS RECONCILING THE 990 TO THE FINANCIAL STATEMENTS TOTALING $44,120 IS THE SPECIAL EVENT IN-KIND SUPPORT DISCLOSED ON THE STATEMENT OF ACTIVITIES OF THE FINANCIAL STATEMENTS.</Explanation>
      </Form990ScheduleDPartXIV>
    </IRS990ScheduleD>
    <IRS990ScheduleF documentId="RetDoc1040500001">
      <GrantRecordsMaintained>1</GrantRecordsMaintained>
      <AcctsActvsOutUSTable>
        <Region>NORTH AMERICA</Region>
        <TypeOfActivitiesConducted>GRANTS TO RECIPIENTS LOCATED IN REGION</TypeOfActivitiesConducted>
        <TotalExpenditures>275000</TotalExpenditures>
      </AcctsActvsOutUSTable>
      <AcctsActvsOutUSTable>
        <Region>EUROPE</Region>
        <TypeOfActivitiesConducted>GRANTS TO RECIPIENTS LOCATED IN REGION</TypeOfActivitiesConducted>
        <TotalExpenditures>1100000</TotalExpenditures>
      </AcctsActvsOutUSTable>
      <AcctsActvsOutUSTable>
        <Region>MIDDLE EAST AND NORTH AFRICA</Region>
        <TypeOfActivitiesConducted>GRANTS TO RECIPIENTS LOCATED IN REGION</TypeOfActivitiesConducted>
        <TotalExpenditures>200000</TotalExpenditures>
      </AcctsActvsOutUSTable>
      <AcctsActvsOutUSTable>
        <Region>EAST ASIA AND THE PACIFIC</Region>
        <TypeOfActivitiesConducted>GRANTS TO RECIPIENTS LOCATED IN REGION</TypeOfActivitiesConducted>
        <TotalExpenditures>275000</TotalExpenditures>
      </AcctsActvsOutUSTable>
      <SubtotalNumberOfEmployees>0</SubtotalNumberOfEmployees>
      <ContNumberOfEmployees>0</ContNumberOfEmployees>
      <TotalNumberOfEmployees>0</TotalNumberOfEmployees>
      <SubtotalAmountSpent>1850000</SubtotalAmountSpent>
      <ContAmountSpent>0</ContAmountSpent>
      <TotalAmountSpent>1850000</TotalAmountSpent>
      <GrantsToOrgsOutsideUS>
        <Region>CALGARY, ALBERTA CANADA</Region>
        <PurposeOfGrant>PAP INHIBITOR AS NOVEL THERAPEUTIC APPROACH IN MULTIPLE MYELOMA</PurposeOfGrant>
        <AmountOfCashGrant>75000</AmountOfCashGrant>
        <MannerOfCashDisbursement>CHECK</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>AUSTRALIA</Region>
        <PurposeOfGrant>THE ROLE OF SURVIVAL PROTEINS IN MULTIPLE MYELOMA DEVELOPMENT</PurposeOfGrant>
        <AmountOfCashGrant>75000</AmountOfCashGrant>
        <MannerOfCashDisbursement>CHECK</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>NETHERLANDS</Region>
        <PurposeOfGrant>THE HUMANIZED MULTIPLE MYELOMA MOUSE MODEL</PurposeOfGrant>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <MannerOfCashDisbursement>CHECK</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>ISREAL</Region>
        <PurposeOfGrant>ERYTHROPOIETIN AS AN ANTI-MULTIPLE MYELOMA IMMUNOMODULATING AGENT</PurposeOfGrant>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <MannerOfCashDisbursement>CHECK</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>CANADA</Region>
        <PurposeOfGrant>DEVELOPMENT OF THERAPEUTIC INHIBITORS FOR TREATMENT OF MULTIPLE MYELOMA.</PurposeOfGrant>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <MannerOfCashDisbursement>CHECK</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>ITALY</Region>
        <PurposeOfGrant>AN INTEGRATED STUDY OF PROTEOSTASIS AGAINST MULTIPLE MYELOMA</PurposeOfGrant>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <MannerOfCashDisbursement>CHECK</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>AUSTRALIA</Region>
        <PurposeOfGrant>TARGETED INHIBITION OF JAK-STAT SIGNALLING TO MODIFY MM DRUG RESISTANCE</PurposeOfGrant>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <MannerOfCashDisbursement>CHECK</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>UNITED KINGDOM</Region>
        <PurposeOfGrant>GLYCOSPHINGOLIPID INHIBITORS IN THE TREATMENT OF MULTIPLE MYELOMA</PurposeOfGrant>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <MannerOfCashDisbursement>CHECK</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <GrantsToOrgsOutsideUS>
        <Region>ITALY</Region>
        <PurposeOfGrant>MINIMAL RESIDUAL DISEASE TO BETTER CHARACTERIZE MULTIPLE MYELOMA RESPONSE AND DETECT EARLY RELAPSE</PurposeOfGrant>
        <AmountOfCashGrant>500000</AmountOfCashGrant>
        <MannerOfCashDisbursement>CHECK</MannerOfCashDisbursement>
      </GrantsToOrgsOutsideUS>
      <TransferToForeignCorp>0</TransferToForeignCorp>
      <InterestInForeignTrust>0</InterestInForeignTrust>
      <OwnForeignCorp>0</OwnForeignCorp>
      <PassiveForeignInvestCo>0</PassiveForeignInvestCo>
      <ForeignPartnership>0</ForeignPartnership>
      <BoycottCountries>0</BoycottCountries>
      <Form990ScheduleFPartV>
        <Identifier>PROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.:</Identifier>
        <Explanation>SCHEDULE F, PART I, LINE 2: GRANTS ARE AWARDED TO INSTITUTIONS FOR A SPECIFIC INVESTIGATORS PROJECT. INSTITUTIONS' BIOTECHNOLOGY COMPANIES OR ACADEMIC MEDICAL CENTERS' MUST HAVE A REPRESENTATIVE AGREE TO AND SIGN OFF ON THE TERMS OF A LEGALLY BINDING CONTRACT BETWEEN THE ORGANIZATION AND THE GRANTEE. THESE CONTRACTS SPECIFY THE ALLOWABLE AND NON-ALLOWABLE COSTS UNDER THE GRANT GUIDELINES AND OUTLINE CORRESPONDING REPORTING REQUIREMENTS. ALL FINANCIAL DOCUMENTS ARE REVIEWED BY ORGANIZATION'S STAFF. SCIENTIFIC REPORTS ARE SENT OUT FOR EXTERNAL PEER REVIEW TO ENSURE THEY ARE IN KEEPING WITH THE PROPOSED SPECIFIC AIMS. GRANTS THAT DEVIATE FROM THOSE AIMS MUST SUBMIT A PLAN FOR THEIR COURSE CORRECTION OR RISK TERMINATION. IF FUNDS HAVE BEEN PAID IN FULL, THE MMRF RESERVES THE RIGHT TO REQUEST A FULL ACCOUNTING AND, IF NECESSARY, REIMBURSEMENT.</Explanation>
      </Form990ScheduleFPartV>
    </IRS990ScheduleF>
    <IRS990ScheduleG documentId="RetDoc1041200001">
      <MailSolicitations>X</MailSolicitations>
      <EmailSolicitations>X</EmailSolicitations>
      <PhoneSolicitations>X</PhoneSolicitations>
      <InPersonSolicitations>X</InPersonSolicitations>
      <SolicitationOfNonGovtGrants>X</SolicitationOfNonGovtGrants>
      <SolicitationOfGovtGrants>X</SolicitationOfGovtGrants>
      <SpecialFundraisingEvents>X</SpecialFundraisingEvents>
      <AgreementRefFundraising>1</AgreementRefFundraising>
      <FundraiserActivityInformation>
        <NameOfOrganization>
          <BusinessNameLine1>ARRON CONSULTING</BusinessNameLine1>
        </NameOfOrganization>
        <AddressUS>
          <AddressLine1>377 FIFTH AVE</AddressLine1>
          <City>BROOKLYN</City>
          <State>NY</State>
          <ZIPCode>11215</ZIPCode>
        </AddressUS>
        <Activity>GREENWICH GALA</Activity>
        <FundraiserControlOfFunds>1</FundraiserControlOfFunds>
        <GrossReceipts>1876168</GrossReceipts>
        <AmountRetainedByContractor>36850</AmountRetainedByContractor>
        <NetToOrganization>1839318</NetToOrganization>
      </FundraiserActivityInformation>
      <FundraiserActivityInformation>
        <NameOfOrganization>
          <BusinessNameLine1>PAT HURLEY</BusinessNameLine1>
        </NameOfOrganization>
        <AddressUS>
          <AddressLine1>205 W WACKER DRIVE 1499</AddressLine1>
          <City>CHICAGO</City>
          <State>IL</State>
          <ZIPCode>60606</ZIPCode>
        </AddressUS>
        <Activity>CHICAGO DINNER</Activity>
        <FundraiserControlOfFunds>1</FundraiserControlOfFunds>
        <GrossReceipts>933060</GrossReceipts>
        <AmountRetainedByContractor>45000</AmountRetainedByContractor>
        <NetToOrganization>888060</NetToOrganization>
      </FundraiserActivityInformation>
      <FundraiserActivityInformation>
        <NameOfOrganization>
          <BusinessNameLine1>ARRON CONSULTING</BusinessNameLine1>
        </NameOfOrganization>
        <AddressUS>
          <AddressLine1>377 FIFTH AVE</AddressLine1>
          <City>BROOKLYN</City>
          <State>NY</State>
          <ZIPCode>11215</ZIPCode>
        </AddressUS>
        <Activity>LAUGH FOR LIFE</Activity>
        <FundraiserControlOfFunds>1</FundraiserControlOfFunds>
        <GrossReceipts>603950</GrossReceipts>
        <AmountRetainedByContractor>18150</AmountRetainedByContractor>
        <NetToOrganization>585800</NetToOrganization>
      </FundraiserActivityInformation>
      <FundraiserActivityInformation>
        <NameOfOrganization>
          <BusinessNameLine1>M3 DEVELOPMENT</BusinessNameLine1>
        </NameOfOrganization>
        <AddressUS>
          <AddressLine1>26 WOODPACKER WAY</AddressLine1>
          <City>MARLBORO</City>
          <State>NJ</State>
          <ZIPCode>07746</ZIPCode>
        </AddressUS>
        <Activity>3.2.1 CAMPAIGN</Activity>
        <FundraiserControlOfFunds>1</FundraiserControlOfFunds>
        <GrossReceipts>0</GrossReceipts>
        <AmountRetainedByContractor>25000</AmountRetainedByContractor>
        <NetToOrganization>-25000</NetToOrganization>
      </FundraiserActivityInformation>
      <FundraiserActivityInformation>
        <NameOfOrganization>
          <BusinessNameLine1>STELTER</BusinessNameLine1>
        </NameOfOrganization>
        <AddressUS>
          <AddressLine1>10435 NEW YORK AVE</AddressLine1>
          <City>DES MOINES</City>
          <State>IA</State>
          <ZIPCode>50322</ZIPCode>
        </AddressUS>
        <Activity>PLANNED GIVING</Activity>
        <FundraiserControlOfFunds>1</FundraiserControlOfFunds>
        <GrossReceipts>0</GrossReceipts>
        <AmountRetainedByContractor>26374</AmountRetainedByContractor>
        <NetToOrganization>-26374</NetToOrganization>
      </FundraiserActivityInformation>
      <TotalGrossReceipts>3413178</TotalGrossReceipts>
      <TotalRetainedByContractors>151374</TotalRetainedByContractors>
      <TotalNetToOrganization>3261804</TotalNetToOrganization>
      <EventsInformation>
        <NameOfEvent1>CORPORATE DINNERS</NameOfEvent1>
        <GrossReceiptsEvent1>2809230</GrossReceiptsEvent1>
        <CharitableContributionsEvent1>2595230</CharitableContributionsEvent1>
        <GrossRevenueEvent1>214000</GrossRevenueEvent1>
        <RentFacilityCostsEvent1>392841</RentFacilityCostsEvent1>
        <EntertainmentEvent1>48898</EntertainmentEvent1>
        <OtherDirectExpensesEvent1>422534</OtherDirectExpensesEvent1>
        <NameOfEvent2>LAUGH PROGRAM</NameOfEvent2>
        <GrossReceiptsEvent2>603950</GrossReceiptsEvent2>
        <CharitableContributionsEvent2>538325</CharitableContributionsEvent2>
        <GrossRevenueEvent2>65625</GrossRevenueEvent2>
        <RentFacilityCostsEvent2>70673</RentFacilityCostsEvent2>
        <EntertainmentEvent2>8550</EntertainmentEvent2>
        <OtherDirectExpensesEvent2>107339</OtherDirectExpensesEvent2>
        <TotalNumberOfOtherEvents>15</TotalNumberOfOtherEvents>
        <GrossReceiptsOtherEvents>3719854</GrossReceiptsOtherEvents>
        <CharitableContribOtherEvents>3719854</CharitableContribOtherEvents>
        <OtherDirectExpensesOtherEvents>818245</OtherDirectExpensesOtherEvents>
        <GrossReceiptsTotal>7133034</GrossReceiptsTotal>
        <CharitableContributionsTotal>6853409</CharitableContributionsTotal>
        <GrossRevenueTotalEvents>279625</GrossRevenueTotalEvents>
        <RentFacilityCostsTotalEvents>463514</RentFacilityCostsTotalEvents>
        <EntertainmentTotalEvents>57448</EntertainmentTotalEvents>
        <OtherDirectExpensesTotalEvents>1348118</OtherDirectExpensesTotalEvents>
        <DirectExpenseSummaryEvents>1869080</DirectExpenseSummaryEvents>
        <NetIncomeSummary>-1589455</NetIncomeSummary>
      </EventsInformation>
    </IRS990ScheduleG>
    <IRS990ScheduleI documentId="RetDoc1041900001">
      <RecordsMaintained>1</RecordsMaintained>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>CONSTELLATION PHARAMCEUTICALS</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>215 FIRST ST SUITE 200</AddressLine1>
          <City>CAMBRIDGE</City>
          <State>MA</State>
          <ZIPCode>02142</ZIPCode>
        </AddressUS>
        <EINOfRecipient>261741721</EINOfRecipient>
        <AmountOfCashGrant>500000</AmountOfCashGrant>
        <PurposeOfGrant>TARGETING HISTONE METHYLTRANSFERASES TO TREAT MULTIPLE MYELOMA</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>DANA FARBER CANCER INSTITUTE</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>44 BINEY ST</AddressLine1>
          <City>BOSTON</City>
          <State>MA</State>
          <ZIPCode>02115</ZIPCode>
        </AddressUS>
        <EINOfRecipient>042263040</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>75000</AmountOfCashGrant>
        <PurposeOfGrant>A NOVEL AURORA KINASE INHIBITOR, AT9283, AND LENALIDOMIDE IN MM</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>DANA FARBER CANCER INSTITUTE</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>44 BINEY ST</AddressLine1>
          <City>BOSTON</City>
          <State>MA</State>
          <ZIPCode>02115</ZIPCode>
        </AddressUS>
        <EINOfRecipient>042263040</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>75000</AmountOfCashGrant>
        <PurposeOfGrant>MEASURING THE APOPTOTIC PRESET AS A PREDICTOR OF CHEMOSENSITIVITY</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>DANA FARBER CANCER INSTITUTE</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>44 BINEY ST</AddressLine1>
          <City>BOSTON</City>
          <State>MA</State>
          <ZIPCode>02115</ZIPCode>
        </AddressUS>
        <EINOfRecipient>042263040</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <PurposeOfGrant>INDUCTION OF MYELOMA CELL SUSCEPTIBILITY TO NK CELLS</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>DANA FARBER CANCER INSTITUTE</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>44 BINEY ST</AddressLine1>
          <City>BOSTON</City>
          <State>MA</State>
          <ZIPCode>02115</ZIPCode>
        </AddressUS>
        <EINOfRecipient>042263040</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <PurposeOfGrant>TARGETING AUTOPHAGY IN MULTIPLE MYELOMA</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>DANA FARBER CANCER INSTITUTE</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>44 BINEY ST</AddressLine1>
          <City>BOSTON</City>
          <State>MA</State>
          <ZIPCode>02115</ZIPCode>
        </AddressUS>
        <EINOfRecipient>042263040</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <PurposeOfGrant>DEVELOPMENT OF COMBINATION REGIMENS BASED ON HISTONE DEACETYLASE INHIBITORS</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>DARTMOUTH MEDICAL SCHOOL NORRIS COTTON CANCER CENTER</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>11 ROPE FERRY RD 6210</AddressLine1>
          <City>HANOVER</City>
          <State>NH</State>
          <ZIPCode>03755</ZIPCode>
        </AddressUS>
        <EINOfRecipient>020222111</EINOfRecipient>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <PurposeOfGrant>MOLECULAR MECHANISMS OF INTRINSIC RESISTANCE OF MYELOMA CELLS TO BORTEZOMIB</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>EPIZYME</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>840 MEMORIAL DRIVE</AddressLine1>
          <City>CAMBRIDGE</City>
          <State>MA</State>
          <ZIPCode>02139</ZIPCode>
        </AddressUS>
        <EINOfRecipient>261349956</EINOfRecipient>
        <AmountOfCashGrant>500000</AmountOfCashGrant>
        <PurposeOfGrant>DEVELOPMENT OF SMALL MOLECULE INHIBITORS OF WH SC1 (MMSET) FOR THE TREATMENT OF T (4;14) MYELOMA PATIENTS</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>H LEE MOFFITT CANCER CENTER</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>12902 MAGNOLIA DRIVE</AddressLine1>
          <City>TAMPA</City>
          <State>FL</State>
          <ZIPCode>33612</ZIPCode>
        </AddressUS>
        <EINOfRecipient>590965591</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <PurposeOfGrant>ROLE OF CALCIUM IN MEDIATING C-HYD1 AND HYD1 INDUCED CELL DEATH IN MM</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>H LEE MOFFITT CANCER CENTER</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>12902 MAGNOLIA DRIVE</AddressLine1>
          <City>TAMPA</City>
          <State>FL</State>
          <ZIPCode>33612</ZIPCode>
        </AddressUS>
        <EINOfRecipient>592451713</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>250000</AmountOfCashGrant>
        <PurposeOfGrant>REGULATION OF MULTIPLE MYELOMA BY MYELOID CELLS</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>INSTITUTION HEALTH RESEARCH INC ROSWELL PARK CANCER INSTITUTE DIVISION</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>ELM AND CARLTON STREET BLSC L5-318B</AddressLine1>
          <AddressLine2>L5-318B</AddressLine2>
          <City>BUFFALO</City>
          <State>NY</State>
          <ZIPCode>14263</ZIPCode>
        </AddressUS>
        <EINOfRecipient>141402155</EINOfRecipient>
        <AmountOfCashGrant>250000</AmountOfCashGrant>
        <PurposeOfGrant>UNDERSTANDING THE MYELOID MICROENVIRONMENT IN MULTIPLE MYELOMA</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>INTELLIKINE</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>10931 NORTH TORREY PINES ROAD SUITE</AddressLine1>
          <AddressLine2>103</AddressLine2>
          <City>LA JOLLA</City>
          <State>CA</State>
          <ZIPCode>92037</ZIPCode>
        </AddressUS>
        <EINOfRecipient>208914077</EINOfRecipient>
        <AmountOfCashGrant>500000</AmountOfCashGrant>
        <PurposeOfGrant>DEVELOPMENT OF INK128, A SELECTIVE TORC1/2 INHIBITOR IN MULTIPLE MYELOMA</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>CRB245 1650 ORLEANS STREET</AddressLine1>
          <City>BALTIMORE</City>
          <State>MD</State>
          <ZIPCode>21287</ZIPCode>
        </AddressUS>
        <EINOfRecipient>520595110</EINOfRecipient>
        <AmountOfCashGrant>500000</AmountOfCashGrant>
        <PurposeOfGrant>QUANTIFICATION OF CIRCULATING TUMOR SPECIFIC DNA IN MULTIPLE MYELOMA</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>KARYOPHARM</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>15 BONTEMPO ROAD</AddressLine1>
          <City>NEWTON</City>
          <State>MA</State>
          <ZIPCode>02459</ZIPCode>
        </AddressUS>
        <AmountOfCashGrant>500000</AmountOfCashGrant>
        <PurposeOfGrant>SMALL MOLECULE CRM1 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>MAYO CLINICMAYO CLINIC COLLEGE OF MEDICINE</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>PO BOX 4006</AddressLine1>
          <City>ROCHESTER</City>
          <State>MN</State>
          <ZIPCode>55905</ZIPCode>
        </AddressUS>
        <EINOfRecipient>416011702</EINOfRecipient>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <PurposeOfGrant>EXPLORING THE ROLE OF UCH-L1 IN THE PATHOGENESIS OF MYELOMA</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>1120 15TH STREET</AddressLine1>
          <City>AUGUSTA</City>
          <State>GA</State>
          <ZIPCode>30912</ZIPCode>
        </AddressUS>
        <EINOfRecipient>581418202</EINOfRecipient>
        <AmountOfCashGrant>75000</AmountOfCashGrant>
        <PurposeOfGrant>THE NFKB2-IL10 PATHWAY IN MULTIPLE MYELOMA PATHOGENESIS</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>MICHIGAN STATE UNIVERSITY</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>301 ADMINISTRATION BUILDING</AddressLine1>
          <City>EAST LANSING</City>
          <State>MI</State>
          <ZIPCode>48824</ZIPCode>
        </AddressUS>
        <EINOfRecipient>386005984</EINOfRecipient>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <PurposeOfGrant>DEVELOPMENT OF ALLOSTERIC PROTEASOME INHIBITORS FOR THE TREATMENT OF MM</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>NORTHWESTERN UNIVERSITY -</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>303 E SUPERIOR STREET LURIE 5-123</AddressLine1>
          <City>CHICAGO</City>
          <State>IL</State>
          <ZIPCode>60611</ZIPCode>
        </AddressUS>
        <EINOfRecipient>362167817</EINOfRecipient>
        <AmountOfCashGrant>250000</AmountOfCashGrant>
        <PurposeOfGrant>ELUCIDATION OF THERAPEUTIC TARGETS IN MMSET-ASSOCIATED MYELOMA</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>10901 NORTH TORREY PINES ROAD</AddressLine1>
          <City>LA JOLLA</City>
          <State>CA</State>
          <ZIPCode>92037</ZIPCode>
        </AddressUS>
        <EINOfRecipient>460450378</EINOfRecipient>
        <AmountOfCashGrant>75000</AmountOfCashGrant>
        <PurposeOfGrant>TARGETING UBC13 FOR MULTIPLE MYELOMA TREATMENT</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>STANFORD UNIVERSITY</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>875 BLAKE WILBUR DRIVE ROOM G-211</AddressLine1>
          <City>STANFORD</City>
          <State>CA</State>
          <ZIPCode>94305</ZIPCode>
        </AddressUS>
        <EINOfRecipient>941156365</EINOfRecipient>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <PurposeOfGrant>TARGETING THE UNFOLDED PROTEIN RESPONSE FOR CANCER THERAPY</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>TGEN</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>445 NORTH 5TH STREET SUITE 423</AddressLine1>
          <City>PHOENIX</City>
          <State>AZ</State>
          <ZIPCode>85004</ZIPCode>
        </AddressUS>
        <EINOfRecipient>753065445</EINOfRecipient>
        <AmountOfCashGrant>250000</AmountOfCashGrant>
        <PurposeOfGrant>CONSEQUENCES OF KDM6A/UTX LOSS IN MULTIPLE MYELOMA</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>THE VA PITTSBURG HEALTHCARE SYSTEM</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>151-U-2W-143 UNIVERSITY DRIVE C</AddressLine1>
          <City>PITTSBURGH</City>
          <State>PA</State>
          <ZIPCode>15240</ZIPCode>
        </AddressUS>
        <EINOfRecipient>250965591</EINOfRecipient>
        <AmountOfCashGrant>250000</AmountOfCashGrant>
        <PurposeOfGrant>THE ROLE OF XBP1S IN MULTIPLE MYELOMA MICROENVIRONMENT</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>TRAGARA</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>10955 VISTA SORRENTO PARKWAY SUITE</AddressLine1>
          <AddressLine2>120</AddressLine2>
          <City>SAN DIEGO</City>
          <State>CA</State>
          <ZIPCode>92130</ZIPCode>
        </AddressUS>
        <EINOfRecipient>320162504</EINOfRecipient>
        <AmountOfCashGrant>500000</AmountOfCashGrant>
        <PurposeOfGrant>DEVELOPMENT OF TG02, A MULTI-KINASE INHIBITOR IN MULTIPLE MYELOMA</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>4301 WEST MARKHAM</AddressLine1>
          <City>LITTLE ROCK</City>
          <State>AK</State>
          <ZIPCode>72205</ZIPCode>
        </AddressUS>
        <EINOfRecipient>716046242</EINOfRecipient>
        <AmountOfCashGrant>250000</AmountOfCashGrant>
        <PurposeOfGrant>IDENTIFICATION OF MOLECULAR TARGETS IN MYELOMA MICROENVIRONMENTS</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>UNIVERSITY OF CALIFORNIA LOS ANGELES</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>11000 KINROSS STREET SUITE 102 3RD</AddressLine1>
          <AddressLine2>FLOOR</AddressLine2>
          <City>LOS ANGELES</City>
          <State>CA</State>
          <ZIPCode>90095</ZIPCode>
        </AddressUS>
        <EINOfRecipient>956006143</EINOfRecipient>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <PurposeOfGrant>TARGETING TYPE 1 IFN AND TRAIL TO MM USING ANTI-CD138 FUSION PROTEINS</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>VIRGINIA COMMONWEALTH UNIVERSITY</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>BOX 843039 730 EAST BROAD ST</AddressLine1>
          <City>RICHMOND</City>
          <State>VA</State>
          <ZIPCode>23298</ZIPCode>
        </AddressUS>
        <EINOfRecipient>546000545</EINOfRecipient>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <PurposeOfGrant>HDAC INHIBITORS AND BH3 MIMETICS IN RESISTANT/REFRACTORY MULTIPLE MYELOMA</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>THE UNIVERSITY OF TEXAS MD ANDERSON CANCE</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>7455 FANNIN</AddressLine1>
          <City>HOUSTON</City>
          <State>TX</State>
          <ZIPCode>77054</ZIPCode>
        </AddressUS>
        <EINOfRecipient>746001118</EINOfRecipient>
        <AmountOfCashGrant>75000</AmountOfCashGrant>
        <PurposeOfGrant>MACROPHAGES PROTECT MYELOMA CELLS FROM CHEMOTHERAPY DRUG-INDUCED APOPTOSIS</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>UT M D ANDERSON CANCER CENTER</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>7455 FANNIN</AddressLine1>
          <City>HOUSTON</City>
          <State>TX</State>
          <ZIPCode>77054</ZIPCode>
        </AddressUS>
        <EINOfRecipient>746001118</EINOfRecipient>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <PurposeOfGrant>MECHANISMS OF LENALIDOMIDE RESISTANCE</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>UNIVERSITY OF UTAH SCHOOL OF MEDICINE</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>201 S PRESIDENTS CIRCLE ROOM 406</AddressLine1>
          <City>SALT LAKE CITY</City>
          <State>UT</State>
          <ZIPCode>84132</ZIPCode>
        </AddressUS>
        <EINOfRecipient>876000525</EINOfRecipient>
        <AmountOfCashGrant>200000</AmountOfCashGrant>
        <PurposeOfGrant>NOVEL TREATMENT APPROACHES TO TARGET THE RARA2 POSITIVE MYELOMA CELL</PurposeOfGrant>
      </RecipientTable>
      <RecipientTable>
        <RecipientNameBusiness>
          <BusinessNameLine1>MULTIPLE MYELOMA RESEARCH CONSORTIUM</BusinessNameLine1>
        </RecipientNameBusiness>
        <AddressUS>
          <AddressLine1>383 MAIN AVENUE</AddressLine1>
          <City>NORWALK</City>
          <State>CT</State>
          <ZIPCode>06851</ZIPCode>
        </AddressUS>
        <EINOfRecipient>810640775</EINOfRecipient>
        <IRCSection>501(C)(3)</IRCSection>
        <AmountOfCashGrant>4145000</AmountOfCashGrant>
        <PurposeOfGrant>CLINICAL DRUG FUNDING</PurposeOfGrant>
      </RecipientTable>
      <TotalNbrOfOtherOrganizations>8</TotalNbrOfOtherOrganizations>
      <Form990ScheduleIPartIV>
        <Identifier>PROCEDURE FOR MONITORING GRANTS IN THE U.S.:</Identifier>
        <ReturnReference>PART I, LINE 2:</ReturnReference>
        <Explanation>SCHEDULE I, PART I, LINE 2: GRANTS ARE AWARDED TO INDIVIDUAL INVESTIGATORS ON BEHALF OF THEIR INSTITUTIONS. INSTITUTIONS' BIOTECHNOLOGY COMPANIES OR ACADEMIC MEDICAL CENTERS' MUST HAVE A REPRESENTATIVE AGREE TO AND SIGN OFF ON THE TERMS OF A LEGALLY BINDING CONTRACT BETWEEN THE ORGANIZATION AND THE GRANTEE. THESE CONTRACTS SPECIFY THE ALLOWABLE AND NON-ALLOWABLE COSTS UNDER THE GRANT GUIDELINES AND OUTLINE CORRESPONDING REPORTING REQUIREMENTS. ALL FINANCIAL DOCUMENTS ARE REVIEWED BY ORGANIZATION'S STAFF. SCIENTIFIC REPORTS ARE SENT OUT FOR EXTERNAL PEER REVIEW TO ENSURE THEY ARE IN KEEPING WITH THE PROPOSED SPECIFIC AIMS. GRANTS THAT DEVIATE FROM THOSE AIMS MUST SUBMIT A PLAN FOR THEIR COURSE CORRECTION OR RISK TERMINATION. IF FUNDS HAVE BEEN PAID IN FULL, THE MMRF RESERVES THE RIGHT TO REQUEST A FULL ACCOUNTING AND, IF NECESSARY, REIMBURSEMENT.</Explanation>
      </Form990ScheduleIPartIV>
    </IRS990ScheduleI>
    <IRS990ScheduleJ documentId="RetDoc1042400001">
      <CompensationCommittee>X</CompensationCommittee>
      <Form990OfOtherOrganizations>X</Form990OfOtherOrganizations>
      <CompensationSurvey>X</CompensationSurvey>
      <BoardOrCommitteeApproval>X</BoardOrCommitteeApproval>
      <SeverancePayment>0</SeverancePayment>
      <SupplementalNonqualRetirePlan>0</SupplementalNonqualRetirePlan>
      <EquityBasedCompArrangement>0</EquityBasedCompArrangement>
      <CompBasedOnRevenueOfFilingOrg>0</CompBasedOnRevenueOfFilingOrg>
      <CompBasedOnRevenueRelatedOrgs>0</CompBasedOnRevenueRelatedOrgs>
      <CompBasedNetEarningsFilingOrg>0</CompBasedNetEarningsFilingOrg>
      <CompBasedNetEarningsRelateOrgs>0</CompBasedNetEarningsRelateOrgs>
      <AnyNonFixedPayments>0</AnyNonFixedPayments>
      <InitialContractException>0</InitialContractException>
      <Form990ScheduleJPartII>
        <NamePerson>KATHY GIUSTI</NamePerson>
        <BaseCompensationFilingOrg>286413</BaseCompensationFilingOrg>
        <CompBasedOnRelatedOrgs>0</CompBasedOnRelatedOrgs>
        <BonusFilingOrg>25000</BonusFilingOrg>
        <BonusRelatedOrgs>0</BonusRelatedOrgs>
        <OtherCompensationFilingOrg>0</OtherCompensationFilingOrg>
        <OtherCompensationRelatedOrgs>0</OtherCompensationRelatedOrgs>
        <DeferredCompFilingOrg>0</DeferredCompFilingOrg>
        <DeferredCompRelatedOrgs>0</DeferredCompRelatedOrgs>
        <NontaxableBenefitsFilingOrg>0</NontaxableBenefitsFilingOrg>
        <NontaxableBenefitsRelatedOrgs>0</NontaxableBenefitsRelatedOrgs>
        <TotalCompensationFilingOrg>311413</TotalCompensationFilingOrg>
        <TotalCompensationRelatedOrgs>0</TotalCompensationRelatedOrgs>
        <CompReportPrior990FilingOrg>0</CompReportPrior990FilingOrg>
        <CompReportPrior990RelatedOrgs>0</CompReportPrior990RelatedOrgs>
      </Form990ScheduleJPartII>
      <Form990ScheduleJPartII>
        <NamePerson>WALTER CAPONE</NamePerson>
        <BaseCompensationFilingOrg>152613</BaseCompensationFilingOrg>
        <CompBasedOnRelatedOrgs>0</CompBasedOnRelatedOrgs>
        <BonusFilingOrg>0</BonusFilingOrg>
        <BonusRelatedOrgs>0</BonusRelatedOrgs>
        <OtherCompensationFilingOrg>0</OtherCompensationFilingOrg>
        <OtherCompensationRelatedOrgs>0</OtherCompensationRelatedOrgs>
        <DeferredCompFilingOrg>0</DeferredCompFilingOrg>
        <DeferredCompRelatedOrgs>0</DeferredCompRelatedOrgs>
        <NontaxableBenefitsFilingOrg>0</NontaxableBenefitsFilingOrg>
        <NontaxableBenefitsRelatedOrgs>0</NontaxableBenefitsRelatedOrgs>
        <TotalCompensationFilingOrg>152613</TotalCompensationFilingOrg>
        <TotalCompensationRelatedOrgs>0</TotalCompensationRelatedOrgs>
        <CompReportPrior990FilingOrg>0</CompReportPrior990FilingOrg>
        <CompReportPrior990RelatedOrgs>0</CompReportPrior990RelatedOrgs>
      </Form990ScheduleJPartII>
      <Form990ScheduleJPartII>
        <NamePerson>LOUISE PERKINS</NamePerson>
        <BaseCompensationFilingOrg>193031</BaseCompensationFilingOrg>
        <CompBasedOnRelatedOrgs>0</CompBasedOnRelatedOrgs>
        <BonusFilingOrg>15000</BonusFilingOrg>
        <BonusRelatedOrgs>0</BonusRelatedOrgs>
        <OtherCompensationFilingOrg>0</OtherCompensationFilingOrg>
        <OtherCompensationRelatedOrgs>0</OtherCompensationRelatedOrgs>
        <DeferredCompFilingOrg>0</DeferredCompFilingOrg>
        <DeferredCompRelatedOrgs>0</DeferredCompRelatedOrgs>
        <NontaxableBenefitsFilingOrg>0</NontaxableBenefitsFilingOrg>
        <NontaxableBenefitsRelatedOrgs>0</NontaxableBenefitsRelatedOrgs>
        <TotalCompensationFilingOrg>208031</TotalCompensationFilingOrg>
        <TotalCompensationRelatedOrgs>0</TotalCompensationRelatedOrgs>
        <CompReportPrior990FilingOrg>0</CompReportPrior990FilingOrg>
        <CompReportPrior990RelatedOrgs>0</CompReportPrior990RelatedOrgs>
      </Form990ScheduleJPartII>
      <Form990ScheduleJPartII>
        <NamePerson>ROBERT LUCAS</NamePerson>
        <BaseCompensationFilingOrg>200417</BaseCompensationFilingOrg>
        <CompBasedOnRelatedOrgs>0</CompBasedOnRelatedOrgs>
        <BonusFilingOrg>0</BonusFilingOrg>
        <BonusRelatedOrgs>0</BonusRelatedOrgs>
        <OtherCompensationFilingOrg>0</OtherCompensationFilingOrg>
        <OtherCompensationRelatedOrgs>0</OtherCompensationRelatedOrgs>
        <DeferredCompFilingOrg>0</DeferredCompFilingOrg>
        <DeferredCompRelatedOrgs>0</DeferredCompRelatedOrgs>
        <NontaxableBenefitsFilingOrg>0</NontaxableBenefitsFilingOrg>
        <NontaxableBenefitsRelatedOrgs>0</NontaxableBenefitsRelatedOrgs>
        <TotalCompensationFilingOrg>200417</TotalCompensationFilingOrg>
        <TotalCompensationRelatedOrgs>0</TotalCompensationRelatedOrgs>
        <CompReportPrior990FilingOrg>0</CompReportPrior990FilingOrg>
        <CompReportPrior990RelatedOrgs>0</CompReportPrior990RelatedOrgs>
      </Form990ScheduleJPartII>
    </IRS990ScheduleJ>
    <IRS990ScheduleM documentId="RetDoc1042900001">
      <SecuritiesPubliclyTraded>
        <NonCashCheckbox>X</NonCashCheckbox>
        <NumberOfContributions>24</NumberOfContributions>
        <NoncashContribsRptdF990>482600</NoncashContribsRptdF990>
        <MethodOfDeterminingRevenues>FMV AT DAY OF RECEIPT/SA</MethodOfDeterminingRevenues>
      </SecuritiesPubliclyTraded>
      <AnyPropertyThatMustBeHeld>0</AnyPropertyThatMustBeHeld>
      <ReviewProcessUnusualNCGifts>0</ReviewProcessUnusualNCGifts>
      <ThirdPartiesUsed>0</ThirdPartiesUsed>
    </IRS990ScheduleM>
    <IRS990ScheduleO documentId="RetDoc1044400001">
      <GeneralExplanation>
        <Identifier>NEW PROGRAM SERVICES</Identifier>
        <ReturnReference>FORM 990, PART III, LINE 2</ReturnReference>
        <Explanation>THE MULTIPLE MYELOMA RESEARCH FOUNDATION, (THE "MMRF") INTENDS TO SPONSOR A MULTI-YEAR PERSONALIZED MEDICINE RESEARCH INITIATIVE IN MULTIPLE MYELOMA. IT BEGAN CERTAIN PROCESSES IN TAX YEAR 2010 IN CONTEMPLATION OF SUCH INITIATIVE AND INTENDS TO START SUCH INITIATIVE BEGINNING IN TAX YEAR 2011. THIS IS A NEW ACTIVITY FOR THE MMRF AS IT WILL BE TAKING ON THE RESPONSIBILITIES OF A SPONSOR OF RESEARCH (E.G., INITIATION, MANAGEMENT, AND/OR FINANCING OF THE RESEARCH) RATHER THAN SIMPLY FUNDING SUCH RESEARCH SPONSORED BY A THIRD PARTY, AS IT HAS DONE PREVIOUSLY. THEREFORE, MMRF IS REPORTING THIS ACTIVITY TO THE IRS AS A CHANGE IN ITS ACTIVITIES PURSUANT TO SECTION III QUESTION 2 OF THIS FORM 990. PURSUANT TO THE MMRF'S CERTIFICATE OF INCORPORATION, ONE OF ITS PURPOSES IS TO "SUPPORT AND PROMOTE IMPROVED TREATMENT AND DEVELOPMENT OF A CURE FOR MULTIPLE MYELOMA... [N]OTWITHSTANDING ANY OTHER PROVISION OF THIS CERTIFICATE OF INCORPORATION, THE OBJECTS AND PURPOSES OF THE CORPORATION SHALL BE EXCLUSIVELY CHARITABLE, SCIENTIFIC AND EDUCATIONAL WITHIN THE MEANING OF CODE SECTION 501(C)(3)." TO MEET THIS PURPOSE, THE MMRF INTENDS TO SPONSOR SCIENTIFIC RESEARCH CARRIED ON IN THE PUBLIC INTEREST TO DISCOVER A CURE FOR MULTIPLE MYELOMA. MMRF INTENDS TO SPONSOR A PERSONALIZED MEDICINE INITIATIVE IN WHICH 1000 OR MORE NEWLY DIAGNOSED PATIENTS WILL BE ENROLLED THROUGH SEVERAL SITES (I.E., HOSPITALS, ACADEMIC MEDICAL CENTERS AND OTHER COMMUNITY HEALTH CENTERS) ACROSS THE COUNTRY. NO EXPERIMENTAL DRUG WILL BE USED IN THE STUDY. RATHER BLOOD AND BONE MARROW SAMPLES WILL BE TAKEN FROM THE PATIENTS PERIODICALLY OVER THE COURSE OF THEIR TREATMENT. THE STANDARD OF CARE (I.E., DRUGS AND TREATMENT) FOR EACH PATIENT WILL BE DETERMINED BY SUCH PATIENT'S PERSONAL PHYSICIAN. THE TISSUES SAMPLES COLLECTED WILL BE PLACED IN A BIOBANK. AN UNRELATED, THIRD PARTY, NOT-FOR-PROFIT BIOMEDICAL RESEARCH INSTITUTE WOULD THEN PERFORM LABORATORY TESTS ON A PORTION OF EACH OF THE SAMPLES RESULTING IN GENOMIC DATA ABOUT EACH PATIENT. THE PURPOSE OF THE RESEARCH STUDY AS SET FORTH IN THE RESEARCH STUDY PROTOCOL IS AS FOLLOWS: "THE OBJECTIVE OF THIS LONGITUDINAL STUDY IS TO IDENTIFY PATIENT SUBGROUPS AND PHENOTYPES DEFINED BY MOLECULAR PROFILING AND CLINICAL FEATURES. THESE PROFILES WILL ENABLE A BETTER UNDERSTANDING OF MECHANISMS OF DISEASE, DRUG RESPONSE AND PATIENT RELAPSE. ULTIMATELY THE STUDY IS INTENDED TO DRIVE SUCCESSFUL DRUG DEVELOPMENT AND PATIENT CARE IN MULTIPLE MYELOMA." BASICALLY, A PERSONALIZED MEDICINE APPROACH LOOKS AT AN INDIVIDUALS GENETIC MAKE UP, ALLOWING PHYSICIANS TO GIVE THE RIGHT DRUG, AT THE RIGHT DOSE, TO THE RIGHT PATIENT, AT THE RIGHT TIME BASED ON THE PATIENT'S GENETIC INFORMATION. IN OTHER WORDS, THE ULTIMATE GOAL OF THE RESEARCH STUDY IS TO COME UP WITH A STANDARD OF CARE MODEL FOR MULTIPLE MYELOMA BASED ON A PATIENT'S GENOMIC DATA. ONCE A CERTAIN NUMBER (E.G., 50) OF PATIENTS' INFORMATION HAS BEEN COLLECTED AND THE GENOMIC DATA PRODUCED FROM THE LABORATORY TESTS CONDUCTED BY THE THIRD PARTY, THE GENOMIC DATA AND THE CLINICAL DATA COLLECTED ON EACH PATIENT, WILL BE PLACED INTO ONE LARGE DATABASE (I.E., THAT CONTAINS BOTH GENOMIC AND CLINICAL DATA) (THE "PATIENT DATA REPOSITORY"). THE PATIENT DATA REPOSITORY WILL THEN BE ACCESSIBLE VIA THE INTERNET TO RESEARCHERS. EACH TIME A NEW MILESTONE NUMBER OF PATIENTS' SAMPLES HAVE BEEN ANALYZED AND GENOMIC INFORMATION DERIVED (E.G., 50, 100, 150, 200 ETC.), SUCH INFORMATION, ALONG WITH THE CLINICAL DATA OF THE RELEVANT PATIENTS, WILL BE POSTED TO THE PATIENT DATA REPOSITORY AND ACCESS GRANTED TO RESEARCHERS. ACCESS TO INFORMATION POSTED TO THE PATIENT DATA REPOSITORY WILL OCCUR AS FOLLOWS: AFTER ANY POSTING OF INFORMATION TO THE PATIENT DATA REPOSITORY, THE MMRF, CERTAIN PRINCIPAL INVESTIGATORS IN MULTIPLE MYELOMA RESEARCH FROM LEADING ACADEMIC MEDICAL CENTERS, CERTAIN SITES WHICH HAVE ENROLLED PATIENTS INTO THE RESEARCH STUDY (E.G., HIGH ENROLLING SITES), A NOT-FOR-PROFIT BIOMEDICAL RESEARCH INSTITUTE WHICH IS A LEADER IN GENOMIC RESEARCH, AND CERTAIN PHARMACEUTICAL AND BIOTECH COMPANIES WILL HAVE ACCESS TO THE INFORMATION FOR THE FIRST NINE MONTHS AFTER EACH POSTING OF INFORMATION. EACH WILL HAVE THE RIGHT TO PUBLISH THEIR FINDINGS (I.E., IN SCIENTIFIC JOURNALS, TREATISE, ETC.) STARTING 9 MONTH AFTER EACH POSTING. AFTER THE FIRST 9 MONTHS FOLLOWING ANY POSTING OF INFORMATION, ANY RESEARCHERS AND ENROLLING SITES INVOLVED IN THE RESEARCH STUDY THAT DID NOT YET HAVE ACCESS TO THE PATIENT DATA REPOSITORY WILL HAVE ACCESS AND BE ABLE TO PUBLISH THEIR FINDINGS. AT THE END OF THE 12TH MONTH FOLLOWING ANY POSTING, THE INFORMATION CONTAINED IN SUCH POSTING WILL BE AVAILABLE TO THE INTERESTED PUBLIC FOR RESEARCH, EDUCATION AND PUBLICATION. FUNDING FOR THE PERSONALIZED MEDICINE INITIATIVE WILL BE DERIVED PRIMARILY (&gt;60%) FROM PRIVATE DONATIONS. SUPPLEMENTAL FUNDING WILL ALSO BE FROM SEVERAL PHARMACEUTICAL AND BIOTECH COMPANIES. THESE COMPANIES WILL NOT HAVE ANY DECISION-MAKING AUTHORITY OVER THE PROTOCOL DESIGN, OVER WHO CAN ACCESS INFORMATION POSTED TO THE PATIENT DATA REPOSITORY, OVER THE CONTENT OF INFORMATION POSTED TO THE PATIENT DATA REPOSITORY, OR OVER WHO CAN ACCESS PATIENT TISSUE. THE SELECTION OF ENROLLING SITES IS IN THE SOLE DISCRETION OF THE MMRF. ALL SCIENTIFIC DECISIONS WILL BE MADE BY A SCIENTIFIC ADVISORY BOARD COMPOSED SOLELY OF NON-INDUSTRY SCIENTISTS AND RESEARCHERS. TISSUE SAMPLES FROM THE PATIENTS IN THE RESEARCH STUDY WILL BE AVAILABLE TO THE ENTITIES AND INDIVIDUALS WHO HAVE HAD ACCESS TO THE PATIENT DATA REPOSITORY, WITH CONSIDERATION GOING TO THE ENTITIES AND RESEARCHERS WHO PARTICIPATED DIRECTLY IN THE RESEARCH STUDY AND WHO CAN MOST EFFICIENTLY AND EFFECTIVELY USE THE SAMPLES IN CONJUNCTION WITH THE INFORMATION POSTED IN THE PATIENT DATA REPOSITORY TO FURTHER A CURE FOR MULTIPLE MYELOMA.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <Identifier>FORM 990, PART VI, SECTION A, LINE 2</Identifier>
        <Explanation>KATHY GIUSTI, CEO AND KAREN ANDREWS, CO-FOUNDER AND BOD MEMBER ARE SISTERS.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <Identifier>FORM 990, PART VI, SECTION A, LINE 3</Identifier>
        <Explanation>JUDITH FINLEY PROVIDED HUMAN RESOURCE SERVICES AND REPORTED DIRECTLY TO THE CEO. KATHY GUISTI.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <Identifier>FORM 990, PART VI, SECTION B, LINE 11</Identifier>
        <Explanation>THE 990 FORM IS REVIEWED INTERNALLY BY THE EXECUTIVE MANAGEMENT WITH NOTIFICATION AND COPIES OF THE 990 SENT TO MEMBERS OF THE BOARD UPON FILING.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <ReturnReference>FORM 990, PART VI, SECTION B, LINE 12C</ReturnReference>
        <Explanation>DUTY TO DISCLOSE A POTENTIAL CONFLICT OF INTEREST. ANY INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF HIS OR HER FINANCIAL INTEREST TO THE BOARD OR CONFLICTS COMMITTEE AND MUST BE GIVEN THE OPPORTUNITY TO DISCLOSE ALL MATERIAL FACTS TO THE BOARD, MEMBERS OF THE CONFLICTS COMMITTEE AND ALL MEMBERS OF ANY COMMITTEE CONSIDERING THE PROPOSED CONTRACT OR TRANSACTION. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS. AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND ALL MATERIAL FACTS, AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR CONFLICTS COMMITTEE MEETING WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR CONFLICT COMMITTEE MEMBERS, AS APPLICABLE, SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST. I. AN INTERESTED PERSON MAY MAKE A PRESENTATION AT THE BOARD OR CONFLICTS COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE OR SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE CONTRACT OR TRANSACTION THAT RESULT IN THE CONFLICT OF INTEREST. II. THE CHAIR OF THE BOARD OR CHAIRPERSON OF THE CONFLICTS COMMITTEE SHALL, IF APPROPRIATE, APPOINT A DISINTERESTED PERSON OR APPOINT OR ESTABLISH AN ADVISORY COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED CONTRACT OR TRANSACTION. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR THE CONFLICTS COMMITTEE SHALL TAKE ALL REASONABLE STEPS TO DETERMINE WHETHER THE MMRF CAN OBTAIN A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. IF A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR CONFLICT COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE, BUT NOT LESS THAN TWO, OF THE DISINTERESTED DIRECTORS OR MEMBERS THEREOF WHETHER THE CONTRACT OR TRANSACTION IS IN THE MMRFS BEST INTEREST AND IS FAIR AND REASONABLE TO THE MMRF; PROVIDED, HOWEVER, IF SUCH CONTRACT OR TRANSACTION IS APPROVED BY DISINTERESTED DIRECTORS WHO DO NOT SATISFY A QUORUM OR VOTING REQUIREMENT APPLICABLE TO THE AUTHORIZATION OF THE ACTION BY REASON OF THE MMRFS CERTIFICATE OF INCORPORATION, BYLAWS OR A PROVISION OF LAW, THE ACTION MUST BE INDEPENDENTLY APPROVED BY SUCH INTERESTED AND DISINTERESTED DIRECTORS AS SATISFY THE APPLICABLE QUORUM OR VOTING REQUIREMENT. VIOLATION OF THE CONFLICTS OF INTEREST POLICY III. IF THE BOARD OR CONFLICTS COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A DIRECTOR, OFFICER OR COMMITTEE MEMBER HAS FAILED TO DISCLOSE ACTUAL OR POSSIBLE CONFLICTS OF INTEREST, IT SHALL INFORM SUCH PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. IF, AFTER HEARING THE RESPONSE OF THE DIRECTOR, OFFICER OR COMMITTEE MEMBER AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR CONFLICTS COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, THE BOARD OR CONFLICTS COMMITTEE, AS APPLICABLE, SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <ReturnReference>FORM 990, PART VI, SECTION B, LINE 15</ReturnReference>
        <Explanation>PROCESS FOR DETERMINING COMPENSATION OF: A. CEO, EXECUTIVE DIRECTOR OR TOP MANAGEMENT OFFICIAL - THE HUMAN RESOURCES COMMITTEE SHALL BE RESPONSIBLE FOR (A) ASSISTING THE BOARD IN ENSURING THAT THE HUMAN RESOURCES AND COMPENSATION POLICES OF THE CORPORATION ARE (I) IN ACCORDANCE WITH ALL LAWS AND REGULATION; (II) WITHIN THE BUDGET APPROVED BY THE BOARD; AND (III) CONDUCIVE TO INDIVIDUAL AND GROUP PRODUCTIVITY AND MORALE; (B) PROVIDING GUIDANCE REGARDING THE CORPORATION'S PERSONNEL POLICIES AND THEIR ADMINISTRATION; (C) KEEPING THE EXECUTIVE COMMITTEE INFORMED OF ANY MATTERS WITH RESPECT TO THE CORPORATIONS' HUMAN RESOURCES, PERSONNEL AND COMPENSATION POLICIES THAT REQUIRE THE ATTENTION OF THE BOARD; (D) REVIEWING THE CORPORATION'S EMPLOYMENT AND PERSONNEL POLICIES AND MONITORING THEIR IMPLEMENTATION; (E) HAVING OVERSIGHT RESPONSIBILITY TO ENSURE THAT THERE ARE WELL-DEFINED PERSONNEL PROCEDURES IN KEEPING WITH BEST STANDARDS AND THAT ALL EMPLOYEES ARE INFORMED IN WRITING ABOUT PERSONNEL POLICIES AND PROCEDURE; (F) REVIEWING AND RECOMMENDING FOR THE EXECUTIVE COMMITTEE'S APPROVAL THE JOB DESCRIPTIONS FOR SENIOR STAFF POSITIONS; (G) ASSISTING MANAGEMENT IN THE ATTRACTION, DEVELOPMENT AND RETENTION OF TOP TALENT; (H) REVIEWING THE EVALUATION OF SENIOR STAFF BY THE CHIEF EXECUTIVE OFFICER AND MAKING RECOMMENDATIONS TO THE EXECUTIVE COMMITTEE AS APPROPRIATE; (I) MAKING RECOMMENDATIONS TO THE EXECUTIVE COMMITTEE CONCERNING THE CHIEF EXECUTIVE OFFICER'S ANNUAL COMPENSATION AND BENEFITS; (J) APPROVING THE CHIEF EXECUTIVE OFFICER'S RECOMMENDATIONS AND ADVISING THE EXECUTIVE COMMITTEE OF SUCH CONCERNING ANNUAL COMPENSATION AND BENEFITS FOR SENIOR MANAGEMENT (INCLUDING NEW HIRES); (K) PROVIDING GUIDANCE TO THE EXECUTIVE COMMITTEE AND THE AUDIT AND FINANCE COMMITTEE WITH REGARD TO OVERALL COMPENSATION AND BENEFIT POLICIES AND (L) ASSISTING IN THE DEVELOPMENT AND RECOMMENDATION TO THE BOARD OF A COMPREHENSIVE SUCCESSION PLAN. SUBJECT TO THE PROVISIONS OF THIS SECTION 5.6, THE HUMAN RESOURCES COMMITTEE SHALL HAVE SUCH ADDITIONAL PURPOSE, MEMBERSHIP, GENERAL AND SPECIFIC FUNCTIONS AND RESPONSIBILITIES AS ARE PROVIDED FOR IN ANY COMMITTEE CHARTER OF THE HUMAN RESOURCES COMMITTEE APPROVED BY THE ENTIRE BOARD. B. OFFICERS OR KEY EMPLOYEES: OFFICERS OF THE COMPANY, ACCORDING TO THE BY-LAWS, ARE: (I) CHAIR OF THE BOARD - NO COMPENSATION PROVIDED (I) CHIEF EXECUTIVE OFFICER (III) CHIEF OPERATING OFFICER (IV) TREASURER (CHIEF FINANCIAL OFFICER) (V) SECRETARY (SENIOR IN-HOUSE COUNSEL). KEY EMPLOYEES ARE: CHIEF SCIENTIFIC OFFICER THESE PERSONS USE THE SAME PROCESS FOR ELECTION BY THE HUMAN RESOURCES COMMITTEE AS DESCRIBED ABOVE FOR ELECTING THE CEO, EXECUTIVE DIRECTOR OR TOP MANAGEMENT OFFICIAL.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <ReturnReference>FORM 990, PART VI, SECTION C, LINE 19</ReturnReference>
        <Explanation>YES DOCUMENTS ARE AVAILABLE TO THE PUBLIC: GOVERNING DOCUMENT - UPON REQUEST CONFLICT OF INTEREST POLICY - UPON REQUEST FINANCIAL STATEMENTS - AVAILABLE ON WEBSITE</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <Identifier>CHANGES IN NET ASSETS OR FUND BALANCES:</Identifier>
        <ReturnReference>FORM 990, PART XI, LINE 5:</ReturnReference>
        <Explanation>NET UNREALIZED GAINS ON INVESTMENTS: 58,346.</Explanation>
      </GeneralExplanation>
      <GeneralExplanation>
        <ReturnReference>FORM 990, PART XII, LINE 2C</ReturnReference>
        <Explanation>THE PROCESS HAS NOT CHANGED</Explanation>
      </GeneralExplanation>
    </IRS990ScheduleO>
    <IRS990ScheduleR documentId="RetDoc1043400001">
      <Form990ScheduleRPartII>
        <NameOfDisregardedEntity>
          <BusinessNameLine1>MULTIPLE MYELOMA RESEARCH CONSORTIUM INC</BusinessNameLine1>
        </NameOfDisregardedEntity>
        <AddressUS>
          <AddressLine1>383 MAIN AVENUE 5TH FLOOR</AddressLine1>
          <City>NORWALK</City>
          <State>CT</State>
          <ZIPCode>06851</ZIPCode>
        </AddressUS>
        <EIN>811640775</EIN>
        <PrimaryActivities>TO ACCELERATE DRUG DEVELOPMENT FOR MULTIPLE MYELOMA &amp;IMPROVE PATIENT OUTCOME</PrimaryActivities>
        <LegalDomicileState>CT</LegalDomicileState>
        <ExemptCodeSection>509 (A) (3)</ExemptCodeSection>
        <PublicCharityStatus>501 (C) (3)</PublicCharityStatus>
        <DirectControllingEntityName>
          <BusinessNameLine1>THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC</BusinessNameLine1>
        </DirectControllingEntityName>
        <ControlledOrg>0</ControlledOrg>
      </Form990ScheduleRPartII>
      <ReceiptOfIntAnnRentsRoyalties>0</ReceiptOfIntAnnRentsRoyalties>
      <GiftGrantOrCapContrToOtherOrg>1</GiftGrantOrCapContrToOtherOrg>
      <GiftGrantOrCapContrFrOtherOrg>0</GiftGrantOrCapContrFrOtherOrg>
      <LoansOrGuaranteesToOtherOrg>0</LoansOrGuaranteesToOtherOrg>
      <LoansOrGuaranteesFromOtherOrg>0</LoansOrGuaranteesFromOtherOrg>
      <SaleOfAssetsToOtherOrg>0</SaleOfAssetsToOtherOrg>
      <PurchaseOfAssetsFromOtherOrg>0</PurchaseOfAssetsFromOtherOrg>
      <ExchangeOfAssets>0</ExchangeOfAssets>
      <RentalOfFacilitiesToOtherOrgs>0</RentalOfFacilitiesToOtherOrgs>
      <RentalOfFacilitiesFrOtherOrgs>0</RentalOfFacilitiesFrOtherOrgs>
      <PerformOfServicesForOtherOrgs>0</PerformOfServicesForOtherOrgs>
      <PerformOfServicesByOtherOrgs>0</PerformOfServicesByOtherOrgs>
      <SharingOfFacilities>1</SharingOfFacilities>
      <SharingOfPaidEmployees>1</SharingOfPaidEmployees>
      <ReimbursementPaidToOtherOrg>0</ReimbursementPaidToOtherOrg>
      <ReimbursementPaidByOtherOrg>0</ReimbursementPaidByOtherOrg>
      <OtherTransferToOtherOrg>0</OtherTransferToOtherOrg>
      <OtherTransferFromOtherOrg>0</OtherTransferFromOtherOrg>
      <TransactionsRelatedOrgsTable>
        <NameOfOtherOrganization>
          <BusinessNameLine1>MULTIPLE MYELOMA RESEARCH CONSORTIUM</BusinessNameLine1>
        </NameOfOtherOrganization>
        <TransactionType>B</TransactionType>
        <AmountInvolved>4145000</AmountInvolved>
      </TransactionsRelatedOrgsTable>
      <TransactionsRelatedOrgsTable>
        <NameOfOtherOrganization>
          <BusinessNameLine1>MULTIPLE MYELOMA RESEARCH CONSORTIUM</BusinessNameLine1>
        </NameOfOtherOrganization>
        <TransactionType>M</TransactionType>
        <AmountInvolved>160097</AmountInvolved>
      </TransactionsRelatedOrgsTable>
      <TransactionsRelatedOrgsTable>
        <NameOfOtherOrganization>
          <BusinessNameLine1>MULTIPLE MYELOMA RESEARCH CONSORTIUM</BusinessNameLine1>
        </NameOfOtherOrganization>
        <TransactionType>N</TransactionType>
        <AmountInvolved>674404</AmountInvolved>
      </TransactionsRelatedOrgsTable>
    </IRS990ScheduleR>
  </ReturnData>
</Return>